Text Size

Pyridylmethylthio derivatives as VEGF inhibitors. Part 1

Tajima H., Honda T., Kawashima K., Sasabuchi Y., Yamamoto M., Ban M., Okamoto K., Inoue K., Inaba T., Takeno Y., Aono H.


  • 2010
  • Bioorganic and Medicinal Chemistry Letters
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Technology

    Pharmacology

  • Categories

    Preclinical development

  • Affiliations

    Research and Development Center, Santen Pharmaceutical Co. Ltd, 8916-16 Takayama-cho Ikoma-shi, Nara 630-0101, Japan; Graduate School of Materials Sciences, Nara Institute of Science and Technology, 8916-5 Takayama-cho Ikoma-shi, Nara 630-0192, Japan

Related Publications

Tolerability and pharmacokinetics of intravitreal sirolimus

Mudumba S., Bezwada P., Takanaga H., Hosoi K., Tsuboi T., Ueda K., Kawazu K., Ali Y., Naor J.


Consensus on evidence gaps and unmet needs in childhood myopia: findings from a European Delphi study with eye care professionals and payers

Lagreze W, Nucci P, Versteegh M, Klaver C, Barrio-Barrio J, Dahlmann-Noor A, Gomez de Liaño R, Ghorbani-Mojarrad N, Kessel L, Polling JR, Sauer A, Schuster AK, Serafino M, Villani E, Ziemssen F, Boehler YB, Capri S, Gianfrate F, Valles Callol JA, Wong O, Chen TY, Lymperopoulou C, Palaka I, Punekar Y, von Bredow D, Shi-van Wielink K.


Economic evaluation, resource utilisation, and associated economic burden of myopia management: a systematic literature review

de Milliano T. WL, Shi-van Wielink K., Ernst F., Mulkalapalli N., Pagidigummula R., Lymperopoulou C.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022